GlobeNewswire

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
20/05/2026
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE [...]
Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform
20/05/2026
ANN ARBOR, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced additional [...]
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
20/05/2026
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate [...]
Emergent BioSolutions to Participate in Upcoming Investor Conferences
20/05/2026
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: [...]
Medline Inc. announces launch of secondary offering of Class A common stock
20/05/2026
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned [...]
Syndax Announces Participation in Upcoming Investor Conferences
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
20/05/2026
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry TORONTO, May 20, 2026 (GLOBE NEWSWIRE [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
20/05/2026
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
20/05/2026
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells IGI’s clinically validated BEAT ® platform enabled the development of [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
20/05/2026
Seasoned biopharmaceutical leaders bring significant clinical development, financial and strategic expertise to support BlossomHill's next phase of growth SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
20/05/2026
No Serious Adverse Events or Adverse Events of Special Interest Were Reported Following 4 Weeks of Treatment SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage [...]
ZoomRx launches Sagan Agents, the AI operating system purpose-built to agentify any pharma customer insights workflow
20/05/2026
Built on 15+ years of proprietary data and life sciences expertise, Sagan Agents transforms how pharma insights teams generate, access, and act on commercial intelligence, compressing customer insights workflows that [...]
Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer’s Clinical Trial at 2nd NovaScan Location Planned for Tampa
20/05/2026
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company ” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to [...]
4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
20/05/2026
Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial momentum CAMBRIDGE, [...]
Final Results and Notice of AGM
20/05/2026
CAMBRIDGE, UK – 20 May 2026 – 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the [...]
Avricore Health Announces $1.25 Million Financing
20/05/2026
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) announces a non-brokered private placement of up to 25,000,000 units ("Units") at a price [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum